COMPOSITIONS FOR TREATMENT OF CARDIOMETABOLIC DISORDERS
The present invention provides for methods of preventing or improving cardiometabolic disorders/metabolic disorders, compositions and pharmaceutical compositions comprising therapeutically effective amount of therapeutic phospholipid compositions and therapeutically effective amount of one or more lipid modifying agents, including statins.
1 . A method of treating a cardiometabolic disorder/metabolic syndrome, the method comprising administering a therapeutically effective amount of a lipid modifying agent and a composition comprising therapeutically effective amount of a phospholipid comprising a glycerol baclbone wherein one of the sn-1 and sn-2 positions is selected from a docosahexaenoic acid (DHA) or an eicosapentaenoic acid (EPA) residue and the other sn-1 and sn-2. position is a fatty acid, to a subject in need thereof.
2 . The method of claim 1 , wherein the lipid modifying agent is selected from the group consisting of statins, ezetimibe, fibrates, niacinamide, and niacin.
3 . The method of claim 1 , wherein the fatty acid is selected from the group consisting of: myristic (14:0); myristoleic (1:4:1); pentadecanoic (15:0); palmitic (16:0); palmitoleic (16:1): stearic (18:0) oleic (18:1); linoleic (18:2 (n-6)); gamma-linolenic (GLA) (18:3 (n-6)); alpha-linolenic (ALA) (18:3 (n-3)); octadecatetraenoic (OTA) (18:4 (n-3)); arachidic (20:0); cis-11-eicosenoic (20:1); eicosadienoic (20.2 (n-6)); methyl ETA (20.3 (n-6)); arachidonic (20:4 (n-6)); homo-γ-linolenic (20:3 (n-3)); eicosatetraeonoic (20:4 (n-3); EPA (20:5 (n-3)); behenic (22:0); erucic (22:1); decosadienoic (C22:2 (n-6)); adrenic (C22:4 (n-6)); methyl DPA (22:5 (n-6)); docosapentaenoic (DPA) (22:5 (n-3)); DHA (22:6 (n-3)); lignoceric (24:0): and nervonic (24:1).
4 . The method of claim 1 , wherein the fatty acid is an omega 3-fatty acid or a fatty acid that is metabolized to an omega 3-fatty acid.
5 . The method of claim 4 , wherein the omega 3-fatty acid or a fatty acid that is metabolized to an omega 3-fatty acid is selected from the group consisting of hexadecatrienoic acid (HTA) (16:3 (n-3)); alpha-linolenic aci d (ALA) (18:3 (n-3)); stearidonic acid (SDA) (18:4 (n-3)); eicosatrienoic acid (ETE) (20:3 (n-3)): eicosatetraenoic acid (ETA) (20:4 (n-3)); eicosapentaenoic acid (EPA) (20:5 (n-3)); heneicosapentaenoic acid (ETA) (21:5 (n-3)); docosapentaenoic acid (DPA) (22:5 (n-3)); docosahexaenoic acid (DHA (22:6 (n-3)); tetracosapentaenoic acid (24:5 (n-3)), and tetracosahexaenoic acid (24:6 (n-3)).
6 . The method of claim 1 , wherein the phospholipid composition is a compound of Formula (I)
wherein R1 and R2, each together with the respective carboxyl groups to which each is attached, each independently represent a docosahexaenoic acid (DHA) or an eicosapentaenoic acid (EPA) resideue, and X is —CH 2 CH 2 NH 3 , —CH 2 CH 2 N(CH 3 ) 3 , or
7 . The method of claim 1 , wherein the cardiometabolic disorder/metabolic syndrome is selected from atheroscelorosis, dyslipidemia, hypertriglycerdimia, hypentensin, heart failure, cardiac arrhythmias, low HDL levels, high LDL levels, stable angina, coronary heart disease, acute myocardial infarction, secondary prevention of myocardial infarction, cardiomyopathy, endocarditis type 2 diabetes, insulin resistance, impaired glucose tolerance, hypercholesterolernia, stroke, hyperlipidemia, hyperlipoprotenemia, chronic kidney disease, intermittent claudication, hyperphosphatemia, omega-3 deficiency phospholipid deficiency, carotid atherosclerosis, peripheral arterial disease, diabetic nephropathy, hypercholesterolemia in HIV infection, acute coronary syndrome (ACS), non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), arterial occlusive diseases, cerebral atherosclerosis, arterioscelerosis, cerebrovascular disorders, myocardial ischemia, coagulopathies leading to thrombus formation in a vessel and diabetic automic neuropathy.
8 . The method of claim 1 , further comprising preventing, reducing or treating elevated cholesterol levels, atherosclerosis, hyperlipidemia, hypercholesterolemia, cardiovascular events and disease including coronary events and cerebrovascular events, and coronary artery disease and/or cerebrovascular disease in a patient in need thereof.
9 . The method of claim 9 , wherein the lipid modifying agent is a statin.
10 . The method of claim 9 , wherein the statin is selected from the group consisting of cerivastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, rosuvastatin, and pitavastein,
11 . The method of claim 9 , wherein the statin is present in less than about 10-50 mg/d.
12 . A pharmaceutical composition comprising a therapeutically effective amount of a lipid modifying agent, selected from the group consisting of statins, ezetimibe, fibrates, niacinamide, niacin and a therapeutically effective amount of a phospholipid composition comprising a glycerol backbone wherein one of the sn-1 and sn-1 positions is selected from a docosahexacnoic acid (DHA) or an eicosapentaenoic acid (EPA) residue and the other sn-1 and sn-2 position is a fatty acid.
13 . The composition of claim 12 , wherein the fatty acid is selected from the group consisting of: myristic (14:0); myristoleic (14:1); pentadecanoic (15:0); palmitic (16:0); palmitoleic (16:1); stearic (18:0); oleic (18:1); linoleic (1.8:2 (n-6); gamma-linolenic (GLA) (18:3 (n-6); alpha-linolenic (ALA) (18:3 (n-3)); octadecatetraenoic (OTA) (18:4 (n-3)); arachidie (20:0); cis-11-eicosenoic (20:1); eicosadienoic (20:2 (n-6); methyl ETA (20:3 (n-6)); arachidonic (20:4 (n-6)); homo-γ-linolenic (20:3 (n-3); eicosaterraenoic (20:4 (n-3)); EPA (20:5 (n-3)); be hen c (22:0); erucie (22:1); docosadienoic (C22:2 (n-6)); adrenic (C22:4 (n-6));: methyl DPA (22:5 (n-6)); docosapentaenoic (DPA) (22:5 (n-3)); DHA (22:6 (n-3)); lignoceric (24:0); and nervonic (24:1).
14 . The composition of claim 12 , wherein the fatty acid is an omega 3-fatty acid or a fatty acid that is metabolized to an omega 3-fatty acid.
15 . The composition of claim 14 , wherein the omega 3-fatty acid or a fatty acid that is metabolized to an omega 3-fatty acid is selected from the group consisting of hexadecatrienoic acid (HTA) (16:3 (n-3)); alpha-linolenic acid (ALA), (18:3 (n-3)); stearidonic acid (SDA) (18:4 (n-3)); eicosatrienoic acid (ETE) (20:3 (n-3)); eicosatetrenoic acid (ETA) (20:4 (n-3)); eicosapentaenoic acid (EPA) (20:5 (n-3)); heneicosapentaenoic acid (HPA) (21:5 (n-3)); docaspentaenoic acid (DPA) (22:5 (n-3)); docosahexacnoic acid (DHA (22:6 (n-3)); tetracosapentaenoic acid (24:5 (n-3)); and tetracosahexacnoic acid (24:6 (n-3)).
16 . The composition of claim 12 , wherein the phospholipid composition is a compound of Formula (I):
wherein R1 and R1, each together with the respective carboxyl groups to which each is attached, each independently represent a docosahexaenoic acid (DHA) or an eicosapentaenoic acid (EPA) residue, and X is —CH 2 CH 2 NH 3 , —CH 2 CH 2 N(CH 3 ) 3 , or
17 . A pharmaceutical composition comprising a therapeutically effective amount of a lipid modifying agent, selected from the group consisting of statins, ezetimibe, fibrates, niacinamide, niacin and a therapeutically effective amount of a phosphoipid compsition comprising a glycerol backbone wherein one of the sn-1 and sn-2 positions is selected from a docosahexaenoic acid (DHA) or an eicosapentaaenoic acid (EPA) residue and the other sn-1 and sn-2 position is a fatty acid.
18 . The composition of claim 17 , wherein the fatty acid is selected from the group consisting of: myristic (14:0); myristoleic (14:1); pentadecanoic (15:0); palmitic (16:0); palmitoleic (16:1); stearic (18:0); oleic (18:1); linoleic (18:2 (n-6)); gamma-linolenic (GLA) (18:3 (n-6)); alpha-linolenic (ALA) (1 8:3 (n-3)); octadecatetraenoic (OTA) (18:4 (n-3)); arachidic (20:0); cis-11-eicosenoic (20:1); eicosadienoic (20:2 (n-6)); methyl ETA (20:3 (n-6)); arachidonic (20:4 (n-6)); homo-γ-linolenic (20:3 (n-3)); eicosatetraenoic (20:4 (n-3)); EPA (20:5 (n-3)); behenic (22:0); erucic (22:1); docosadienolc (C22:2 (n-6)); adrenic (C22:4 (n-6)); methyl DPA (22:5 (n-6)); docosapentaenoic (DPA) (22:5 (n-3)); DHA (22:6 (n-3)); lignoceric (24:0); and nervonic (24:1).
19 . The composition of claim 17 , wherein the fatty acid is an omega 3-fatty acid or a fatty acid that is metabolized to an omega 3-fatty acid.
20 . The composition of claim 19 , wherein the omega 3-fatty acid or a fatty acid that is metabolized to an omega 3-fatty acid is selected from the group consisting of: hexadecatrienoic acid (HTA) (16:3 (n-3)); alpha-linolenic acid (ALA) (18:3 (n-3)), stearidonic acid (SDA) (18:4 (n-3)); eicosatrienoic acid (ETE) (20:3 (n-3)); eicosatetraenoic acid (ETA) (20:4 (n-3)); eicosapentaenoic acid (EPA) (20:5 (n-3)); beneicosapentacnoic acid (HPA) (21:5 (n-3)); docosaperitaenoic acid (DPA) (22:5 (n-3)); docosahexaenok acid (DHA (22:6 (n-3)); tetracosapentaenoic acid (24:5 (n-3)); and tetracosahexaenoic acid (24:6 (n-3)).
21 . The composition of claim 17 , wherein the phospholipid composition is a compound of Formula (I):
wherein R1 and R2, each together with the respective carboxyl groups to which eas is attached, each independently represent a docasahexaenoic acid (DHA) or an taehed,. e.ah independentiy represent a doeosatlexatnoic acid (DHA) or on eicosapentaenoic acid (EPA) residue, and X is —CH 2 CH 2 NH 3 , —CH 2 CH 2 M(CH 3 ) 3 , or